Prof Claudia Mauri

Photo

Personal Profile

Name: Claudia Mauri Email: c.mauri@ucl.ac.uk
Title: Prof Tel: 004420310882155
Department: Inflammation Fax:
Position: Professor of Immunology Address: 5 UNIVERSITY STREET, , London, W1T 4JF
Research Domain: Experimental Medicine, Infection, Immunology & Inflammation, Personalised Medicine Web Page: Personal Web Page

Profile

Research Description

Harnessing the regulatory properties of B cells in the therapy of autoimmune disease. B cells are conventionally regarded as effector cells capable of producing antibodies against invading pathogens or, in the case of autoimmunity, against self-antigens. However, a body of evidence is now emerging, suggesting that B cells also play a regulatory role in the evolution of immune responses, chiefly through their interactions with T cells. I was amongst the first three groups in the world to identify a novel subset of B cells with strong suppressive capacity. Our original observation showed that activation of arthritogenic splenocytes with agonistic anti-CD40 gave a raise to a B cell population producing high levels of interleukin-10 (IL-10) and low levels of Interferon-? (IFN-?). Adoptive transfer of this B cell subset prevents disease development and ameliorates established arthritis (JEM, 2003). In 2007 we have phenotypically identified regulatory B cells and demonstrated that they are contained within the transitional 2 B cells subset (T2-Breg). (JI 2007)(Trends in Immunol. 2008). We are currently translating the results from the experimental model to healthy individuals as well as to patients with rheumatoid arthritis and to patients with SLE and have recently "pinned down" the phenotype and the mechanisms of action. Anti-TNF? therapy regulates CD4+CD25high T cells levels and function in rheumatoid arthritis. Regulatory T cells have been clearly implicated in the control of disease in murine models of autoimmunity. The paucity of data regarding the role of these lymphocytes in human autoimmune disease has prompted us to examine their function in patients with rheumatoid arthritis (RA). We have demonstrated that regulatory T cells isolated from patients with active RA, although still anergic, were unable to suppress pro-inflammatory cytokines released by T cells and monocytes. In addition, these regulatory T cells lack the ability to convey a suppressive phenotype to neighbouring effector T cells. The functional defect was not permanent, as suppressive activity was restored after anti-TNF? treatment. Furthermore, anti-TNF? treatment lead to a significant rise in the peripheral blood regulatory T cells of RA patients responding to this treatment, which correlated with a reduction in C Reactive Protein (CRP). This work was done in collaboration with Prof. M. Ehrenstein and was the first study demonstrating that regulatory T cells are functionally compromised in RA, suggesting that modulation of regulatory T cells by anti-TNF_ therapy may be a further mechanism by which this disease is ameliorated (2004,JEM). Consequentially, we have extended our previous observation and demonstrated that anti-TNF? blockade can lead to induction of regulatory T cells and has the potential for restoring tolerance (2007 JEM). Recently we have characterized the molecular defect of regulatory T cell in patients with RA and unravelled that the lack of suppression is due to an abnormal recirculation of CTLA-4, molecule important for the maintenance of tolerance.

Research Activities

Immunoregulation in rheumatic disease

Education Description

Course organiser (with Dr Antoniou) for IMM3009, IMM3008.

UCL Collaborators

Prof Mala Maini; Prof David Isenberg; Prof Mike Ehrenstein; Dr Liz Jury

External Collaborators

Publications

    2014

    • Rosser EC, Blair PA, Mauri C (2014). Cellular targets of regulatory B cell-mediated suppression.. Mol Immunol, , - . doi:10.1016/j.molimm.2014.01.014
    • Todd SK, Pepper RJ, Draibe J, Tanna A, Pusey CD, Mauri C, Salama AD (2014). Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis.. Rheumatology (Oxford), , - . doi:10.1093/rheumatology/keu136
    • Mauri C, Blair PA (2014). Regulatory B cells: Are we really ready to manipulate them for the benefit of patients with autoimmune diseases?. Arthritis Rheumatol, , - . doi:10.1002/art.38667
    • Litman GW, Mauri C (2014). Editorial overview: Lymphocyte development.. Curr Opin Immunol, , - . doi:10.1016/j.coi.2014.02.008

    2013

    • Mauri C (2013). Cross-Talk Between Regulatory B Cells and Invariant Natural Killer T Cells Under Homeostatic Conditions and During Inflammation.
    • Menon M, Bosma A, Isenberg DA, Mauri C (2013). Defective crosstalk between regulatory B cells and plasmacytoid dendritic cells contributes to the pathogenesis of systemic lupus erythematosus.
    • Rosser EC, Tonon S, Doyle R, Bosma A, Carter NA, Harris KA, Klein N, Mauri C (2013). Gut-microbiota induced IL-1 beta and IL-6 control the differentiation of regulatory B cells.
    • Hofmann SC, Bosma A, Bruckner-Tuderman L, Isenberg DA, Jury E, Mauri C (2013). The reduction of circulating invariant natural killer T cells in lupus erythematosus patients is associated with enrichment at the site of cutaneous inflammation.
    • Hofmann SC, Bosma A, Bruckner-Tuderman L, Vukmanovic-Stejic M, Jury EC, Isenberg DA, Mauri C (2013). Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus.. J Dermatol Sci, 71(1), 22 - 28. doi:10.1016/j.jdermsci.2013.04.012
    • Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C (2013). CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.. Sci Transl Med, 5(173), 173ra23 - . doi:10.1126/scitranslmed.3005407

    2012

    • Mauri C (2012). REGULATORY B CELLS IN HEALTHY AND IN PATIENTS WITH SLE. ANNALS OF THE RHEUMATIC DISEASES, 71, 22 - 22.
    • Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C (2012). Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells.. Immunity, 36(3), 477 - 490. doi:10.1016/j.immuni.2012.02.008
    • Cross A, Strom A, Cole J, Goddard M, Hultgardh-Nilsson A, Nilsson J, Mauri C, Monaco C (2012). B regulatory cells mediate atheroprotection via IL-10.
    • McGovern J, Notley CA, Nguyen D, Mauri C, Isenberg DA, Ehrenstein MR (2012). Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis.
    • Bouma G, Carter NA, Recher M, Notarangelo LD, Burns SO, Mauri C, Thrasher AJ (2012). DEFICIENCY OF REGULATORY B CELLS IN WISKOTT-ALDRICH SYNDROME PROTEIN DEFICIENT MICE LEADS TO EXACERBATED AUTOIMMUNE ARTHRITIS.
    • Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U, Kennedy PT, Brunetto M, Lampertico P, Mauri C, Maini MK (2012). IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.. J Immunol, 189(8), 3925 - 3935. doi:10.4049/jimmunol.1103139
    • Mauri C, Bosma A (2012). Immune regulatory function of B cells.. Annu Rev Immunol, 30, 221 - 241. doi:10.1146/annurev-immunol-020711-074934
    • McGovern J, Nguyen DX, Notley CA, Mauri C, Isenberg D, Ehrenstein M (2012). ANTI-TNF ANTIBODY THERAPY, BUT NOT TNF RECEPTOR BLOCKADE, INDUCES IL-17 SUPPRESSING REGULATORY T CELLS.
    • McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR (2012). Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.. Arthritis Rheum, 64(10), 3129 - 3138. doi:10.1002/art.34565
    • Mauri C (2012). Regulatory B cells in healthy and in patients with sle. doi:10.1016/j.cyto.2012.06.312
    • Carter NA, Rosser EC, Mauri C (2012). Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis.. Arthritis Res Ther, 14(1), R32 - . doi:10.1186/ar3736

    2011

    • Carter NA, Vasconcellos R, Rosser EC, Tulone C, Muñoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C (2011). Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.. J Immunol, 186(10), 5569 - 5579. doi:10.4049/jimmunol.1100284
    • Bosma A, Abdel-Gadir A, Isenberg DA, Mauri C, Jury EC (2011). Lipid-Antigen Presentation by CD1d(+) B Cells Is Essential for the Maintenance of Inkt Cells: Aberrant B Cells From Patients with Systemic Lupus Erythematosus Impair Inkt Cell Homeostasis.
    • Hofmann SC, Bosma A, Bruckner-Tuderman L, Isenberg DA, Jury EC, Mauri C (2011). Invariant natural killer T cells in lesional skin of lupus erythematosus patients.
    • Vasconcellos R, Carter NA, Rosser EC, Mauri C (2011). IL-12p35 subunit contributes to autoimmunity by limiting IL-27-driven regulatory responses.. J Immunol, 187(6), 3402 - 3412. doi:10.4049/jimmunol.1100224
    • Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011). B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.. Proc Natl Acad Sci U S A, 108(26), 10662 - 10667. doi:10.1073/pnas.1100994108
    • Carter NA, Jayasinghe SN, Mauri C (2011). Biosprayed spleen cells integrate and function in mouse models.. Analyst, 136(17), 3434 - 3437. doi:10.1039/c1an15154a

    2010

    • Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, Ehrenstein MR (2010). Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus.. Eur J Immunol, 40(2), 569 - 578. doi:10.1002/eji.200939781
    • Bosma A, Vasconcellos R, Carter NA, Isenberg DA, Jury EC, Mauri C (2010). LIPID ANTIGEN PRESENTATION BY B CELLS IS IMPORTANT TO TRIGGER INKT CELL EXPANSION FOR MEDIATION OF AN ANTI-INFLAMMATORY RESPONSE.
    • Mauri C, Jury EC (2010). Could the expression of CD86 and FcγRIIB on B cells be functionally related and involved in driving rheumatoid arthritis?. Arthritis Res Ther, 12(4), 133 - . doi:10.1186/ar3092
    • Mauri C (2010). Regulation of immunity and autoimmunity by B cells.. Curr Opin Immunol, 22(6), 761 - 767. doi:10.1016/j.coi.2010.10.009
    • Mauri C, Carter NA, Flores-Borja F, Blair PA (2010). More than T regs, the relevance of other lymphocytes.
    • Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C (2010). Auto-reactive B cells in systemic lupus erythematosus patients impair iNKT cell frequency and function, which is restored after B cell depletion therapy.
    • Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C (2010). Auto-reactive B cells in systemic lupus erythematosus patients impair iNKT cell frequency and function, which is restored after B cell depletion therapy.
    • Carter NA, Vasconcellos R, Rosser EC, Mauri C (2010). The IL-12p35 subunit, but not IL-12, suppresses the immunosuppressive pathway driven by IL-27.
    • Flores-Borja F, Cambridge G, Ng D, Turi M, Ehrenstein MR, Isenberg D, Mauri C (2010). Regulatory B cells prevent the differentiation of naive CD4(+)T-cells into TH1 and TH17 but favour FOXP3+Tregs development.
    • McGovern J, Notley CA, Nguyen XD, Mauri C, Isenberg DA, Ehrenstein MR (2010). Anti-TNF antibody therapy in patients with rheumatoid arthritis, but not TNF receptor blockade, induces IL-17 suppressing regulatory T cells.
    • Mauri C, Blair PA (2010). Regulatory B cells in autoimmunity: developments and controversies.. Nat Rev Rheumatol, 6(11), 636 - 643. doi:10.1038/nrrheum.2010.140
    • Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (2010). CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.. Immunity, 32(1), 129 - 140. doi:10.1016/j.immuni.2009.11.009

    2009

    • Mauri C, Carter N (2009). Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs.. Arthritis Res Ther, 11(4), 237 - . doi:10.1186/ar2752
    • Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, Ehrenstein MR, Mauri C (2009). Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice.. J Immunol, 182(6), 3492 - 3502. doi:10.4049/jimmunol.0803052

    2008

    • Das A, Ellis G, Blair P, Brunetta M, Lopes AR, Khanna P, Dusheiko G, Peppa D, Mauri C, Maini M (2008). Role of IL-10-producing regulatory B-cells in chronic HBV infection.
    • Carter NA, Tulone C, Ehrenstein MR, Mauri C (2008). Chimeric mice with B cells deficient in IL-10 develop exacerbated collagen-induced arthritis and have an increased pro-inflammatory phenotype.
    • Notley C, Mauri C, Ehrenstein M (2008). The importance of natural IgM in the immune system: scavenger, protector and regulator..
    • Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR (2008). Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.. Proc Natl Acad Sci U S A, 105(49), 19396 - 19401. doi:10.1073/pnas.0806855105
    • Datta SK, Mauri C (2008). Signalling defects and cellular interactions (2).. Lupus, 17(3), 247 - 250.
    • Abbas S, Mauri C (2008). Characterisation of IL10 producing B cells in patients with RA and healthy individuals.
    • Blair PA, Chavez-Rueda KA, Abbas S, Schlomchik MJ, Isenberg DA, Ehrenstein MR, Mauri C (2008). CD21HI CD23+ CD24HI regulatory B cells in MRL/LPr mice and SLE patients.
    • Murphy K, Travers P, Walport M (2008). Immunobiology seventh edition. In (Ed.), Immunobiology seventh edition (pp. - ). : Garland.
    • Jury EC, Flores-Borja F, Isenberg DA, Mauri C, Ehrenstein MR (2008). Abnormal CTLA-4 function in lupus patients is associated with induction of a defective population of FOXP3+regulatory T cells via TGF.
    • Flores-Borja F, Mauri C, Ehrenstein MR (2008). Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis. European Journal of Immunology, 38(4), 934 - 937.
    • Mauri C, Ehrenstein MR (2008). The 'short' history of regulatory B cells.. Trends in Immunology, 29(1), 34 - 40.

    2007

    • Mauri C, Blair AP, Chavez AK, Evans J, Eddaodi A, Ehrenstein MR (2007). Suppression of experimental lupus by "regulatory" transitional 2 B cells.
    • Nadkarni S, Mauri C, Ehrenstein MR (2007). Anti-TNF-{alpha} therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-{beta}. Journal of Experimental Medicine, 204(1), 33 - 39. doi:10.1084/jem.20061531
    • Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ E, M M, C (2007). Novel suppressive function of transitional 2 B cells in experimental arthritis.. The Journal of Immunology, 15(178), 7868 - 7878.
    • Mauri C, Ehrenstein MR (2007). Cells of the synovium in rheumatoid arthritis. B cells.. Arthritis Research and Therapy, 9(2), 205 - .
    • Ehrenstein MR, Mauri C (2007). If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine.. Journal of Experimental Medicine, 204(10), 2249 - 2252.
    • Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C (2007). Novel suppressive function of transitional 2 B cells in experimental arthritis.. J Immunol, 178(12), 7868 - 7878.

    2006

    • Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006). Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.. The Journal of Immunology, 177(10), 7416 - 7422.

    2005

    • Jury EC, Mauri C, Ehrenstein MR (2005). The immunomodulatory effects of atorvastatin may be mediated by disruption of membrane microdomains.
    • Ehrenstein MR, Evans J, Mathews C, Choudry F, Mauri C (2005). Regulatory T cells in rheumatoid arthritis before and after anti-TNF? Therapy.
    • Chavez K, Ehrenstein M, Evans J, Mauri C (2005). Could B cells have the potential to control lupus-like syndrome in MRL/lpr?.
    • Mathews CJ, Evans J, Choudry F, Ehrenstein MR, Mauri C (2005). Characterization of regulatory T cells in rheumatoid arthritis before and after treatment with anti-TNF alpha therapy.
    • Manson JJ, Mauri C, Ehrenstein MR (2005). Natural serum IgM maintains immunological homeostasis and prevents autoimmunity.. Springer Seminars in Immunopathology, 26(4), 425 - 432.
    • Jury EC, Mauri C, Ehrenstein M (2005). The immunomodulatory effects of atorvastatin may be mediated by disruption of membrane microdomains.
    • Jury EC, Mauri C, Ehrenstein MR (2005). Investigation into the effects of atorvastatin on lipid rafts and T cell function in patients with systemic lupus erythematosus..
    • Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2005). The HMG-coA reductase inhibitor atorvastatin targets lipid rafts in lupus T cells leading to restoration of their function.
    • Ehrenstein MR, Jury EC, Mauri C (2005). Statins for atherosclerosis--as good as it gets?. New England Journal of Medicine, 352, 73 - 75.

    2004

    • Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004). Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice.. The Journal of Immunology, 173(12), 7641 - 7646.
    • Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004). Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.. Journal of Experimental Medicine, 200(3), 277 - 285. doi:10.1084/jem.20040165
    • Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M (2004). Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.. Proceedings of the National Academy of Sciences of the United States of America, 101(15), 5634 - 5639.
    • Ehrenstein MR, Evans JG, Singh A, Moore S, Isenberg DA, Mauri C (2004). DEFECTS IN THE GENERATION AND FUNCTION OF REGULATORY T CELLS IN RHEUMATOID ARTHRITIS: REVERSAL BY ANTI-TNF alpha THERAPY. RHEUMATOLOGY, 43, 20 - 20.
    • Ehrenstein MR, Mauri C (2004). Compromised function of regulatory T cells in rheumatoid arthritis: Reversal by anti-TNF alpha therapy.
    • Schiavoni G, Mauri C, Carlei D, Belardelli F, Pastoris MC, Proietti E (2004). Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway.. The Journal of Immunology, 173(2), 1266 - 1275.

    2003

    • Mauri C, Feldmann M, Williams RO (2003). Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response.. Arthritis Rheum, 48(3), 839 - 845. doi:10.1002/art.10832
    • Mauri C, Gray D, Mushtaq N, Londei M (2003). Prevention of arthritis by interleukin 10-producing B cells. Journal of Experimental Medicine, 197(4), 489 - 501. doi:10.1084/jem.20021293
    • Mauri C, Feldmann M, Williams RO (2003). Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response.. Arthritis and Rheumatism, 48, 839 - 845. doi:10.1084/jem.20021293
    • Ehrenstein MR, Evans JG, Singh A, Moore S, Isenberg DA, Mauri C (2003). Expansion of regulatory (CD4+CD25hi) T lymphocytes in the peripheral blood of patients with rheumatoid arthritis who respond to anti-TNF therapy.

    2000

    • Mauri C, Mars LT, Londei M (2000). Therapeutic activity of agonistic anti-CD40 mAb in a chronic autoimmune inflammatory process. FASEB J, 14(6), A1101 - A1101.
    • Marinova-Mutafchieva L, Williams RO, Mauri C, Mason LJ, Walmsley MJ, Taylor PC, Feldmann M, Maini RN (2000). A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.. Arthritis and Rheumatism, 43, 638 - 644.
    • Mauri C, Mars L T LM (2000). Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.. Nature Medicine, 6, 673 - 679.

    1998

    • Williams RO, Mauri C, Mason LJ, Marinova M, Ross SE, Feldmann M, Maini RN (1998). Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. ARTHRITIS RHEUM, 41(10), 1806 - 1812.
    • Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F (1998). Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.. Journal of Clinical Investigation, 101, 429 - 441.

    1997

    • Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchiev AL, Malfait AM, Maini RN, Feldmann M (1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.. The Journal of Immunology, 159, 6253 - 6259.
    • (1997). Suckling CD1 mice as an animal model for studies of Legionella pneumophila virulence.. Journal of Medical Microbiology, 46, 647 - 655.
    • Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN (1997). Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA).. Clinical and Experimental Immunology, 107, 507 - 512.
    • Mauri C, Chu CQ, Woodrow D, Mori L, Londei M (1997). Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody.. J Immunol, 159(10), 5032 - 5041.
    • Mauri C, Chu CQ, Woodrow D, Mori L, Londei M (1997). Related Articles, Links Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody.. The Journal of Immunology, 159, 5032 - 5041.

    1996

    • Mauri C, Williams RO, Marinova L, Maini RN, Feldmann M (1996). Th1/Th2 response in CIA: Dominant role of IFN gamma and IL-12 in the induction of arthritis. ARTHRITIS RHEUM, 39(9), 217 - 217.
    • Mauri C, Williams RO, Walmsley M, Feldmann M (1996). Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis.. European Journal of Immunology, 26, 1511 - 1518.

    • Todd SK (). B regulatory cells are numerically but not functionally impaired in AAV. doi:10.1016/j.lpm.2013.02.019
    • Flores-Borja F, Jury E, Ehrenstein MRACM (). Defect in CTLA-4 expression are associated with abnormal T regulatory cells function in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, , - .